Curtis Lockshin, Ph.D.
Dr. Lockshin comes to RXi providing exceptional industry insight and functional, hands-on experience. He currently serves as the CEO of Guardum Pharmaceuticals, LLC in Lexington, MA, a wholly owned US subsidiary of OJSC Pharmsynthez which is headquartered in St. Petersburg, Russia. Prior to this role, Dr. Lockshin served as Vice President, Corporate R&D Initiatives for OPKO Health, Inc., with operational responsibilities inside several of OPKO’s R&D units. He currently serves as a Director of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. He previously served as a Director of Sorrento Therapeutics and Winston Pharmaceuticals. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor’s new leads initiative. He is a Co-Inventor on several U.S. patents and applications, covering pharmaceuticals, biomaterials, and optics for remote biochemical sensing. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.